Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer

NCT06519292 is registered in ClinicalTrials.gov with Hanneke W. M. van Laarhoven as lead sponsor.

NCT NCT06519292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06519292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer
Lead sponsor
Hanneke W. M. van Laarhoven
Phase
Observational
Overall status
Recruiting
Start date
January 25, 2023
Completion date
December 31, 2025
Enrollment
214 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arterial thrombosis, atherosclerosis, cancer, cardiovascular diseases, coronary artery disease, myocardial infarction, stroke